India Inc. delivered strong March-quarter earnings, surpassing market forecasts. Revenue growth improved, supported by cost savings. Howeve...

The Indian IT sector's recent interest is seen as tactical, not structural, as banking stocks show fatigue. Rising crude oil prices are dri...

Geopolitical tensions necessitate a disciplined, diversified investment approach, according to Systematix Group's Nikhil Khandelwal. He adv...

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...

Emerging Markets led global returns in 2025, but India lagged due to outflows and weaker earnings. With valuations correcting and domestic ...

Pharma stocks showed strength on Thursday, defying market weakness. Dr Reddy's Laboratories saw significant gains, fueled by anticipation o...

India’s rural economy faces pressure in 2026 from a likely El Niño-driven weak monsoon and rising input costs due to US-Iran tensions. Lowe...

Global demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...

Pharma stocks fell Thursday after reports of US President Donald Trump mulling 100% tariffs on imported branded and patented medicine maker...

Indian equities enter 2026 on a mature footing, shifting from liquidity-driven gains to an earnings-focused environment. Investors must pri...

Wockhardt’s breakthrough respiratory drug Zaynich moves a step closer to market as the US FDA accepts it for review, boosting approval odds...

India Inc's optimism for the second half of FY26 is tempered by muted Q2 earnings, with companies focusing on cost control. While markets a...

Dhananjay Sinha of Systematix Group suggests a cautious market outlook. Upcoming results season, tariff concerns, and US Fed rate decisions...

So I would say US has started to move on a positive trajectory. Earlier it was on a declining trajectory and a cause of concern for most co...

Shares of the Hyderabad-based pharmaceutical ingredient company closed at ₹3,297 apiece on the NSE. The stock touched an intraday low of ₹3...

“One large sector continues to be banks and the entire BFSI space. Second, the entire industrial and capital goods basket, which is facing ...

The company plans to invest the funds to strengthen its team and enhance technology to differentiate and deliver best in class services to ...